BeiGene | A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

⟵ Back to Search Results

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Beigene Study ID

BGB-3111-309

ClinicalTrials.gov ID

NCT05707377

EudraCT Number

2022-501147-32-00

China Drug Trials ID

CTR20230546

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Locations

Sex: All

Age: 18 Years / 75 Years

No Study Documents